Ketamine is classified as a Schedule III managed material under the Managed Substance Act and, as pointed out above, approved from the FDA for anesthetic indications [seventy three]. Common adverse effects affiliated with anesthetic ketamine use involve emergence reactions, hemodynamic instability, and respiratory depression. These signs are very rarely described https://walterw011rft8.wikibriefing.com/user